U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 4Cl.Pt
Molecular Weight 336.896
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PLATINUM TETRACHLORIDE

SMILES

[Cl-].[Cl-].[Cl-].[Cl-].[Pt+4]

InChI

InChIKey=FBEIPJNQGITEBL-UHFFFAOYSA-J
InChI=1S/4ClH.Pt/h4*1H;/q;;;;+4/p-4

HIDE SMILES / InChI

Molecular Formula Pt
Molecular Weight 195.084
Charge 4
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24515615 | https://www.ncbi.nlm.nih.gov/pubmed/19587824 | https://www.ncbi.nlm.nih.gov/pubmed/7737155 | https://www.ncbi.nlm.nih.gov/pubmed/7923207

Diamminedichlorodihydroxyplatinum IV is the platinum-based antineoplasticis agent. Oxaliplatin is cis, cis, trans- isomer of Diamminedichlorodihydroxyplatinum IV. Oxaliplatin show high stability and therefore can be utilized orally for outpatient care. Although oxoplatin is capable of binding directly to DNA after prolonged incubation, platinum(IV) agents are considered to be largely inert prodrugs that are converted to highly cytotoxic platinum(II) compounds by reducing substances, enzymes, or microenvironmental conditions. Reaction of oxoplatin with 0.1 M hydrogen chloride mimicking gastric acid yields cis-diammine-tetrachlorido-platinum(IV) (DATCP[IV]), which exhibits two-fold increased activity. The oxoplatin metabolite DATCP(IV) constitutes a potent cytotoxic derivative that may be produced by gastric acid or acidic areas prevailing in larger solid tumors, depending on the respective pharmaceutical formulation of oxoplatin.

Originator

Sources: Zhurnal Neorganicheskoi Khimii Volume 2, Pages 2349-59, Journal, 1957

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2311221
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Role of p38 MAPK in the selective release of IL-8 induced by chemical allergen in naive THp-1 cells.
2008 Mar
Identification of contact and respiratory sensitizers according to IL-4 receptor α expression and IL-2 production.
2012 Apr 15
Gene expressions changes in bronchial epithelial cells: markers for respiratory sensitizers and exploration of the NRF2 pathway.
2014 Mar
Patents

Sample Use Guides

After single i.v. administration of trans-dihydroxy-cis-dichlorodiammine-platinum(IV), the LD50 values have been calculated to range between 80 and 130 mg/kg in mice, and between 22 and 45 mg/kg in rats.
Route of Administration: Intravenous
The DNA binding/capture studies were done in a total volume of 20 μL containing 38.5 μM (bp) pBR322 DNA (New EnglandBioLabs Inc.), in 12 mM HEPES, N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonicacid (pH 7.4) buffer or, when sodium bicarbonate was present, in 12 mM HEPES buffer plus 12 mM sodium bicarbonate (pH 7.4). The two reducing agents used were glutathione (GSH, 2 mM) and ascorbic acid (AsA, 50 μM). Stock solutions of the platinum compound Diamminedichlorodihydroxyplatinum IV in distilled water was in the range of 40–650 μM. Appropriate volumes of the stock solutions were added to solutions containing the buffer and DNA to give the final concentrations given earlier and values of r, where r=[platinum compound]/[DNA-bp], given in the captions to figures. The samples were incubated at 37 °C for 24 h in sealed Eppendorf tubes after which time 2.5 μL of a loading dye containing 50% glycerol, 0.25% bromophenol blue and 0.25% xylene cyanol was added. An 8 μL volume of each sample containing the loading dye was loaded in the wells of a 1% agarose gel. Electrophoresis was carried out for a period of ~4 h, at 100 V. After electrophoresis, the gel was immersed in 300 mL of deionized water containing 300 μL of a 0.5 mg/mL solution of ethidium bromide for 30 min to stain the DNA, and then soaked in water alone for 15 min to de-stain the background of the gel. A digital image of the stained gel was captured using a Kodak Gel Logic 100 imaging system equipped with Fisher Biotech IT-88A transilluminator.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:56:56 GMT 2023
Edited
by admin
on Sat Dec 16 08:56:56 GMT 2023
Record UNII
W3YUG71TU2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PLATINUM TETRACHLORIDE
WHO-DD  
Systematic Name English
PLATINUM(IV) TETRACHLORIDE
Systematic Name English
TETRACHLOROPLATINUM
Systematic Name English
Platinum tetrachloride [WHO-DD]
Common Name English
PLATINUM CHLORIDE (PTCL4), (SP-4-1)-
Systematic Name English
PLATINUM CHLORIDE (PTCL4)
Common Name English
PLATINUM (IV) CHLORIDE [HSDB]
Common Name English
Code System Code Type Description
SMS_ID
100000127765
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
ECHA (EC/EINECS)
236-645-1
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
PUBCHEM
26031
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
HSDB
6346
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
WIKIPEDIA
Platinum(IV) chloride
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID601014389
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
CAS
13454-96-1
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
EVMPD
SUB33877
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY
FDA UNII
W3YUG71TU2
Created by admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
PRIMARY